Stockscreener 앱 받기
30.42
11.35%
3.10
시간 외 거래:
31.00
0.58
+1.91%
전일 마감가:
$27.32
열려 있는:
$27.66
하루 거래량:
3.18M
Relative Volume:
2.55
시가총액:
$2.51B
수익:
-
순이익/손실:
$-154.65M
주가수익비율:
-12.79
EPS:
-2.3786
순현금흐름:
$-142.43M
1주 성능:
+9.58%
1개월 성능:
+16.15%
6개월 성능:
-29.83%
1년 성능:
+119.16%
1일 변동 폭
$27.00
$31.11
1주일 범위
$26.08
$31.11
52주 변동 폭
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
30.42 | 2.25B | 0 | -154.65M | -142.43M | -2.3786 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys therapeutics MLYS: Chief medical officer sells $59k in shares - Investing.com India
Mineralys (MLYS) CMO exercises options and sells 2,170 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) insider sales and RSU vesting disclosed - Stock Titan
Affiliate sale of 14,058 shares and multiple David Rodman trades (MLYS) - Stock Titan
(MLYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Sentiment Recap: Whats the profit margin of Mineralys Therapeutics Inc2026 Key Highlights & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Catalysts: What is Mineralys Therapeutics Incs revenue forecastQuarterly Portfolio Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn
Retail Trends: What are the future prospects of Mineralys Therapeutics Inc2026 Sentiment & Community Shared Stock Ideas - baoquankhu1.vn
Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise - Stock Titan
Form DEFA14A Mineralys Therapeutics, - StreetInsider
Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections - Stock Titan
Signal Recap: What are the future prospects of Mineralys Therapeutics Inc2026 Snapshot & Weekly High Return Stock Forecasts - baoquankhu1.vn
Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy? - Yahoo Finance
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? - Yahoo Finance
Profit Recap: Is Mineralys Therapeutics Inc impacted by rising ratesQuarterly Growth Report & Low Drawdown Trading Techniques - baoquankhu1.vn
Why Mineralys Therapeutics Stock Is Surging Today - TipRanks
Mineralys Therapeutics, Inc. (MLYS) stock price, news, quote and history - Yahoo Finance UK
Avalyn Appoints Biopharmaceutical Veteran to Board - National Today
Avalyn Appoints Jon Congleton To Board - citybiz
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors - The Manila Times
Mineralys Therapeutics (MLYS) garnering attention with lorundrostat progress - MSN
Earnings Miss: Whats the RSI of Mineralys Therapeutics Inc stock2026 Levels & Capital Protection Trading Alerts - baoquankhu1.vn
Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock By Investing.com - Investing.com Australia
Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares - MarketBeat
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 3,000 Shares of Stock - MarketBeat
Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock By Investing.com - Investing.com Australia
Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock - Investing.com
Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock - Investing.com
Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k - Stock Titan
Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan - Stock Titan
IPO Launch: How sensitive is Mineralys Therapeutics Inc to inflationMarket Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Mineralys Therapeutics (NASDAQ:MLYS) Director Acquires $7,354,269.00 in Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - theglobeandmail.com
Mineralys Therapeutics Surges on FDA Milestone Buzz - TipRanks
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Insider Monkey
Mineralys Therapeutics(MLYS.US) Director Buys US$8.76 Million in Common Stock - 富途牛牛
Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares - Stock Titan
Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan
RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares - Stock Titan
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 12.4%What's Next? - MarketBeat
Investors Purchase High Volume of Mineralys Therapeutics Put Options (NASDAQ:MLYS) - marketbeat.com
Immunic appoints biopharmaceutical executive Jon Congleton to board - Yahoo! Finance Canada
Ex-Copaxone launch executive joins Immunic board as MS trial nears - stocktitan.net
(MLYS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
SG Americas Securities LLC Buys 130,758 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Major Insider Power Move Signals Growing Confidence in Mineralys Therapeutics - TipRanks
Mineralys Therapeutics, Inc.Common Stock (NQ: MLYS - FinancialContent
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):